NEW HAVEN, Conn., Aug. 6, 2008 (PRIME NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that it has entered into definitive agreements for $31.1 million and up to an additional $10.4 million in a private placement financing with a select group of institutional investors led by ProQuest Investments, and joined by Clarus Ventures and Investor Growth Capital, Inc.
